Challenging Cases in Non-Muscle Invasive Bladder Cancer (NMIBC) – Drs. Shilpa Gupta & Joshua Meeks

Rethinking Treatment for Low-Grade NMIBC: When Less May Be More

Watch Dr. Daneshmand discuss #BladderCancer updates #NMIBC — https://bit.ly/NMIBC25-Y

Emerging NMIBC Therapies: Mechanisms & Trial Insights

Understanding NMIBC Biomarkers: A Practical Guide

Therapy for High Risk NMIBC

Strategies for Neoadjuvant and Adjuvant Therapies in NMIBC

Tailoring Treatments in Intermediate-risk NMIBC

High-Risk NMIBC During BCG Shortages: What’s the Safest Path?

Combination Therapies & Results in NMIBC

Sequencing Therapies in NMIBC Management w/ Dr. Mark Tyson & Dr. Suzanne Merrill | Ep. 26

How AI and Imaging Could Transform NMIBC Care

Integrating Molecular Data into NMIBC Management

Botox, Acupuncture & Bladder Preservation in Complex NMIBC Cases

How to Treat Bladder Cancer – Drs. Stephanie Berg (Medical Oncologist) & Joshua Meeks (Urologist)

The Evolving Role of Medical Oncology in NMIBC

Clinical Insights: Evolving Landscape of Bladder Cancer After GU ASCO 2026

NMIBC: Cost-Effective Treatment Strategies

Can Biomarkers Guide NMIBC Treatment Sequencing?

Inlexzo – The New FDA-Approved Bladder Cancer Breakthrough Explained

AI & Risk Stratification in NMIBC

Treatments and Challenges in BCG-refractory NMIBC

When It’s Time for Cystectomy: Key Red Flags in NMIBC

Navigating High-Risk NMIBC in the Era of BCG Shortage

MANAGEMENT OF NON MUSCLE INVASIVE BLADDER CANCER (NMIBC)

Contemporary Diagnostics in NMIBC w/ Dr. Anne Shuckman and Piyush Agarwal | Tumor Board Ep. 24

How Biomarkers Enhance Precision Medicine in NMIBC w/ Dr. Katie Murray & Dr. Sarah Psutka | Ep. 28

Guide to Patient-Centered Counseling in NMIBC Care w/ Dr. Sima Porten & Dr. Patrick Hensley | Ep. 25

Trial vs. Real-World Results: What Clinicians Should Expect in NMIBC

Treatment of High-Risk NMIBC: What's New? w/ Dr. Ashish Kamat | Urology Podcast Ep. 177

Established Biomarkers in NMIBC Care

BCG vs Gemcitabine + Docetaxel for Treatment-Naïve Intermediate-Risk NMIBC: Comparative Study

Variant Histology in NMIBC: Impact on Upstaging & Survival After Radical Cystectomy

NMIBC Tumor Board: Nuances in Management w/ Dr. Mark Tyson & Dr. Sarah Psutka | Tumor Board Ep. 30

Patient-Centered Treatment Options for Intermediate Risk NMIBC